These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24156504)

  • 1. Biologic agents in nail psoriasis: efficacy data and considerations.
    Kyriakou A; Patsatsi A; Sotiriadis D
    Expert Opin Biol Ther; 2013 Dec; 13(12):1707-14. PubMed ID: 24156504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic nail disease: quality of life and treatment.
    Gupta AK; Cooper EA
    J Cutan Med Surg; 2009; 13 Suppl 2():S102-6. PubMed ID: 19799826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).
    Sánchez-Regaña M; Aldunce Soto MJ; Belinchón Romero I; Ribera Pibernat M; Lafuente-Urrez RF; Carrascosa Carrillo JM; Ferrándiz Foraster C; Puig Sanz L; Daudén Tello E; Vidal Sarró D; Ruiz-Villaverde R; Fonseca Capdevila E; Rodríguez Cerdeira MC; Alsina Gibert MM; Herrera Acosta E; Marrón Moya SE;
    Actas Dermosifiliogr; 2014 Dec; 105(10):923-34. PubMed ID: 24852726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis.
    Bardazzi F; Antonucci VA; Tengattini V; Odorici G; Balestri R; Patrizi A
    J Dtsch Dermatol Ges; 2013 Nov; 11(11):1065-70. PubMed ID: 24119121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Crowley JJ; Weinberg JM; Wu JJ; Robertson AD; Van Voorhees AS;
    JAMA Dermatol; 2015 Jan; 151(1):87-94. PubMed ID: 25471223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
    Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
    J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to managing patients with nail psoriasis.
    Reich K
    J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nail psoriasis and biologics.
    Noiles K; Vender R
    J Cutan Med Surg; 2009; 13(1):1-5. PubMed ID: 19298765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked improvement in nail psoriasis during treatment with etanercept.
    Gómez Vázquez M; Navarra Amayuelas R
    Dermatol Ther; 2011; 24(5):498-500. PubMed ID: 22353156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Puig L; Carrascosa JM; Carretero G; de la Cueva P; Lafuente-Urrez RF; Belinchón I; Sánchez-Regaña M; García-Bustínduy M; Ribera M; Alsina M; Ferrándiz C; Fonseca E; García-Patos V; Herrera E; López-Estebaranz JL; Marrón SE; Moreno JC; Notario J; Rivera R; Rodriguez-Cerdeira C; Romero A; Ruiz-Villaverde R; Taberner R; Vidal D;
    Actas Dermosifiliogr; 2013 Oct; 104(8):694-709. PubMed ID: 24018211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nail psoriasis with adalimumab: an open label unblinded study.
    Rigopoulos D; Gregoriou S; Lazaridou E; Belyayeva E; Apalla Z; Makris M; Katsambas A; Ioannides D
    J Eur Acad Dermatol Venereol; 2010 May; 24(5):530-4. PubMed ID: 19807825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked improvement in nail psoriasis during treatment with adalimumab.
    Irla N; Yawalkar N
    Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result.
    Ricceri F; Pescitelli L; Tripo L; Bassi A; Prignano F
    Dermatol Ther; 2013; 26(1):77-8. PubMed ID: 23384024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.
    Al-Mutairi N; Nour T; Al-Rqobah D
    Expert Opin Biol Ther; 2013 May; 13(5):625-9. PubMed ID: 23527597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alefacept in the treatment of psoriatic nail disease: a proof of concept study.
    Parrish CA; Sobera JO; Robbins CM; Cantrell WC; Desmond RA; Elewski BE
    J Drugs Dermatol; 2006 Apr; 5(4):339-40. PubMed ID: 16673801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.
    Tokuyama M; Ota M; Saitoh R; Sawamura M; Okitsu N; Shimizu T; Kondoh A; Yamaoka H; Mabuchi T
    Tokai J Exp Clin Med; 2020 Dec; 45(4):230-235. PubMed ID: 33300595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.